Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Clin Pharmacol
2017 May 01;835:1082-1096. doi: 10.1111/bcp.13186.
Show Gene links
Show Anatomy links
In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
Mamidi RNVS
,
Dallas S
,
Sensenhauser C
,
Lim HK
,
Scheers E
,
Verboven P
,
Cuyckens F
,
Leclercq L
,
Evans DC
,
Kelley MF
,
Johnson MD
,
Snoeys J
.
???displayArticle.abstract???
AIMS: Canagliflozin is a recently approved drug for use in the treatment of type 2 diabetes. The potential for canagliflozin to cause clinical drug-drug interactions (DDIs) was assessed.
METHODS: DDI potential of canagliflozin was investigated using in vitro test systems containing drug metabolizing enzymes or transporters. Basic predictive approaches were applied to determine potential interactions in vivo. A physiologically-based pharmacokinetic (PBPK) model was developed and clinical DDI simulations were performed to determine the likelihood of cytochrome P450 (CYP) inhibition by canagliflozin.
RESULTS: Canagliflozin was primarily metabolized by uridine 5'-diphospho-glucuronosyltransferase 1A9 and 2B4 enzymes. Canagliflozin was a substrate of efflux transporters (P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein-2) but was not a substrate of uptake transporters (organic anion transporter polypeptide isoforms OATP1B1, OATP1B3, organic anion transporters OAT1 and OAT3, and organic cationic transporters OCT1, and OCT2). In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1). Basic models recommended in DDI guidelines (US Food & Drug Administration and European Medicines Agency) predicted moderate to low likelihood of interaction for these CYPs and efflux transporters. PBPK DDI simulations of canagliflozin with CYP probe substrates (simvastatin, S-warfarin, bupropion, repaglinide) did not show relevant interaction in humans since mean areas under the concentration-time curve and maximum plasma concentration ratios for probe substrates with and without canagliflozin and its 95% CIs were within 0.80-1.25.
CONCLUSIONS: In vitro DDI followed by a predictive or PBPK approach was applied to determine DDI potential of canagliflozin. Overall, canagliflozin is neither a perpetrator nor a victim of clinically important interactions.
Alexander,
The Concise Guide to PHARMACOLOGY 2015/16: Transporters.
2015, Pubmed
Alexander,
The Concise Guide to PHARMACOLOGY 2015/16: Transporters.
2015,
Pubmed
Alexander,
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.
2015,
Pubmed
Bjornsson,
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.
2003,
Pubmed
Chester,
Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
2003,
Pubmed
Devineni,
Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
2015,
Pubmed
Devineni,
Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants.
2015,
Pubmed
Devineni,
Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
2015,
Pubmed
Devineni,
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
2015,
Pubmed
Devineni,
Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
2013,
Pubmed
Innocenti,
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
2004,
Pubmed
Lagas,
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
2006,
Pubmed
Liang,
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
2012,
Pubmed
Lin,
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
2011,
Pubmed
Mamidi,
In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
2018,
Pubmed
,
Xenbase
Mamidi,
Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
2014,
Pubmed
Miners,
Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin.
2018,
Pubmed
Patel,
Variability of acetaminophen metabolism in Caucasians and Orientals.
1992,
Pubmed
Polidori,
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
2013,
Pubmed
Prescott,
Paracetamol overdosage. Pharmacological considerations and clinical management.
1983,
Pubmed
Rosenstock,
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
2012,
Pubmed
Sha,
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
2011,
Pubmed
Southan,
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.
2016,
Pubmed
Wilding,
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
2013,
Pubmed
Williams,
Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.
2004,
Pubmed
van Waterschoot,
Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
2010,
Pubmed
van Waterschoot,
Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
2010,
Pubmed